Reported Saturday, Merck And Eisai's Phase 3 LEAP-012 Trial OF KEYTRUDA-LENVIMA Combo Shows 34% Reduction In Progression For Advanced Liver Cancer
Reported Saturday, Merck And Eisai's Phase 3 LEAP-012 Trial OF KEYTRUDA-LENVIMA Combo Shows 34% Reduction In Progression For Advanced Liver Cancer
报道称，默沙东和爱文思控股的第3阶段LEAP-012试验显示，Keytruda-Lenvima组合在爱文思控股肝癌晚期患者中显示出34%的疗效提升。
- In the Phase 3 LEAP-012 trial, KEYTRUDA plus LENVIMA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone
- Late-breaking first interim analysis results are being presented during a Presidential Symposium session at the European Society for Medical Oncology Congress 2024
- 在第3期LEAP-012试验中，与单独TACE相比，KEYTRUDA加LENVIMA联合应用可将疾病进展或死亡风险减少34%。
- 这些突破性的初步分析结果将在2024年欧洲医学肿瘤学会议的主题讨论会上进行报道。
资讯热榜
更新时间